AR124034A1 - MODULADORES PPARg Y MÉTODOS DE USO - Google Patents

MODULADORES PPARg Y MÉTODOS DE USO

Info

Publication number
AR124034A1
AR124034A1 ARP210103111A ARP210103111A AR124034A1 AR 124034 A1 AR124034 A1 AR 124034A1 AR P210103111 A ARP210103111 A AR P210103111A AR P210103111 A ARP210103111 A AR P210103111A AR 124034 A1 AR124034 A1 AR 124034A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
hydrogen
halogens
alkyls
formula
Prior art date
Application number
ARP210103111A
Other languages
English (en)
Inventor
Sudeep Prajapati
Hyelee Lee
Stephanos Ioannidis
Kiyoyuki Omoto
Alan Rolfe
Xiang Liu
Megan Sheehan
Paul Dransfield
Andrew Cook
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR124034A1 publication Critical patent/AR124034A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: Ar¹ se elige entre los compuestos de fórmula (2) y (3) en donde Y¹ se elige entre N y C-X¹ en donde X¹ se elige entre hidrógeno, hidroxilo, halógenos y alquilos C₁₋₄; R³ se elige entre hidrógeno, alquilos opcionalmente sustituidos, aminas opcionalmente sustituidas, halógenos, ciano y alcoxis opcionalmente sustituidos; y R⁴ se elige entre hidrógeno y alquilos opcionalmente sustituidos; cada Y² se elige entre C-X² y N e Y³ es NH, o Y² es NH e Y³ es C-X², en donde X² se elige entre hidrógeno y halógenos; el Anillo A se elige entre anillos cíclicos saturados de 6 a 9 miembros opcionalmente sustituidos con al menos un sustituyente elegido entre halógenos, hidroxilo y alquilos opcionalmente sustituidos; R¹ se elige entre -(CHR⁵)ₖ-(CR⁶R⁷)ₙ-(O)ₘ-Anillo B, en donde k es 0 ó 1, n es 0 ó 1, m es 0 ó 1, R⁵ se elige entre hidrógeno y alquilos opcionalmente sustituidos, R⁶ se elige entre hidrógeno y halógenos, R⁷ se elige entre hidrógeno y halógenos, y el Anillo B se elige entre arilos opcionalmente sustituidos, heteroarilos opcionalmente sustituidos, cicloalquilos opcionalmente sustituidos, heterocicloalquilos opcionalmente sustituidos, cicloalquenilos opcionalmente sustituidos, y heterocicloalquenilos opcionalmente sustituidos; y R² se elige entre hidrógeno y alquilos opcionalmente sustituidos. Reivindicación 28: Una composición farmacéutica que comprende al menos una entidad elegida entre compuestos de fórmula (1) y sales farmacéuticamente aceptables de los mismos de acuerdo con una cualquiera de las reivindicaciones 1 a 27.
ARP210103111A 2020-11-09 2021-11-09 MODULADORES PPARg Y MÉTODOS DE USO AR124034A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063111354P 2020-11-09 2020-11-09

Publications (1)

Publication Number Publication Date
AR124034A1 true AR124034A1 (es) 2023-02-08

Family

ID=78820026

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103111A AR124034A1 (es) 2020-11-09 2021-11-09 MODULADORES PPARg Y MÉTODOS DE USO

Country Status (12)

Country Link
US (1) US20230062861A1 (es)
EP (1) EP4240736A1 (es)
JP (1) JP2023549123A (es)
KR (1) KR20230107291A (es)
CN (1) CN116635380A (es)
AR (1) AR124034A1 (es)
AU (1) AU2021376300A1 (es)
CA (1) CA3200524A1 (es)
IL (1) IL302543A (es)
MX (1) MX2023005371A (es)
TW (1) TW202233598A (es)
WO (1) WO2022099144A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023219879A1 (en) * 2022-05-09 2023-11-16 Eisai R&D Management Co., Ltd. SOLID FORM OF PPAR-gamma MODULATORS AND METHODS OF USE
CN117800895A (zh) * 2022-09-30 2024-04-02 苏州阿尔脉生物科技有限公司 草酸胺类衍生物、包含其的药物组合物及其医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562031B1 (en) 2015-09-12 2017-02-07 Sequoia Sciences, Inc. Phenethyldihydrobenzodioxolones and methods of use
US10525048B2 (en) * 2015-09-18 2020-01-07 Memorial Sloan Kettering Cancer Center Methods and compositions of inhibiting DCN1-UBC12 interaction
EP3498694A1 (en) * 2017-12-12 2019-06-19 Medibiofarma, S.L. New benzamide derivatives as ppar-gamma modulators

Also Published As

Publication number Publication date
IL302543A (en) 2023-07-01
CA3200524A1 (en) 2022-05-12
AU2021376300A9 (en) 2024-10-10
WO2022099144A1 (en) 2022-05-12
US20230062861A1 (en) 2023-03-02
JP2023549123A (ja) 2023-11-22
AU2021376300A1 (en) 2023-06-22
EP4240736A1 (en) 2023-09-13
KR20230107291A (ko) 2023-07-14
TW202233598A (zh) 2022-09-01
CN116635380A (zh) 2023-08-22
MX2023005371A (es) 2023-05-22

Similar Documents

Publication Publication Date Title
AR124034A1 (es) MODULADORES PPARg Y MÉTODOS DE USO
AR110346A1 (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
AR114950A1 (es) Compuestos de benzamida
AR116109A1 (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR108130A1 (es) Derivados de pirazolopirimidina
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
AR058198A1 (es) Derivados de morfolina y composiciones farmaceuticas
CO5690588A2 (es) Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
AR112338A2 (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
AR114828A1 (es) Compuestos de pteridinona y sus usos
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
AR105911A1 (es) Inhibidores de hdac8 bicíclicos fusionados [6,6]
AR062666A1 (es) Benzotriazoles como moduladores de quinasas
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR104415A1 (es) Compuestos antiestrogénicos derivados de cromeno
AR087792A1 (es) Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR101561A1 (es) Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona
AR111874A1 (es) Derivados de pirimidina
PE20230182A1 (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
AR126914A1 (es) Inhibidores de ras novedosos